Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elenbecestat - Biogen/Eisai

Next Previous
X
Search
Drug Profile

Elenbecestat - Biogen/Eisai

Alternative Names: E-2609

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Developer Biogen; Eisai Inc; GE Healthcare
  • Class Antidementias; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 13 Sep 2019 Discontinued - Phase-I for Alzheimer's disease in USA (PO), after September 2019
  • 13 Sep 2019 Discontinued - Phase-III for Alzheimer's disease (Early-stage disease) in China, Taiwan, South Africa, Slovakia, Singapore, Portugal, Mexico, Italy, Hungary, Finland, Denmark, Croatia, Chile, United Kingdom, Poland, South Korea, Greece, Germany, France, Czech Republic, Bulgaria, Canada, Australia, Argentina, Spain, Austria, Japan, USA (PO), after September 2019
  • 13 Sep 2019 Eisai terminates a phase II trial in Alzheimer's disease in USA as a consequence of the discontinuation of MISSION AD1 and MISSION AD2 trials as per the recommendation of the Data Safety Monitoring Board (DSMB) due to unfavorable risk-benefit ratio (PO) (NCT02322021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top